Back in the early 1990s, hormone therapies for prostate cancer revolved around blocking or starving the cancer of androgens. Most treatments handled this partially, but researchers saw that the tumor still crept forward. That fueled the drive for compounds that could knock out androgen production at its root. Scientists at the Institute of Cancer Research and the Royal Marsden Hospital in London spearheaded abiraterone’s development. They targeted cytochrome P450 17A1 (CYP17A1), a key enzyme cancer cells exploit to make their own androgens. After a decade of preclinical lab work and clinical testing, the idea turned into reality. The FDA approved abiraterone acetate in 2011 for men with metastatic castration-resistant prostate cancer (mCRPC) who already tried docetaxel. That approval marked a new chapter for patients running out of options.
Abiraterone comes as abiraterone acetate, a prodrug that converts into active abiraterone in the body. Doctors combine it with prednisone to keep side effects in check. The drug targets androgen production, blocking steroid synthesis, and shrinking tumors fueled by hormones. You’ll find abiraterone in oral tablet form, supplied in several strengths by pharmaceutical brands under names like Zytiga and Yonsa. It’s prescription-only, strictly regulated, and dispensed through specialty pharmacies.
The pure compound presents as a white to off-white powder, showing very slight solubility in water but good solubility in organic solvents like methanol. Its chemical name, (3β)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol, and its molecular formula, C24H31NO, anchor it in the category of steroidal molecules. The drug carries a molecular weight of about 349.5 g/mol, and crystallizes in several polymorphic forms, important for formulation stability. Its melting point falls between 225°C and 230°C, reflecting the compound’s tightly packed steroid structure.
Each tablet’s dose is usually 250 mg, labeled for oral administration in combination with corticosteroids to minimize adrenal insufficiency. The packaging lists whether the tablets contain lactose, warnings for pregnancy, and directions for storage away from humidity and light. Clear warnings lay out risks of hypertension, hypokalemia, and fluid retention. Barcodes track dispensing, and every batch carries traceable information to manage recalls and adverse event monitoring. Guidelines for professionals run pages, highlighting the need for liver tests before and during treatment, because abiraterone can push up liver enzyme results if unchecked.
Chemists build abiraterone from a steroidal backbone. They start with raw androstane materials, often from plant sterols. The process demands a careful orchestration of reduction, oxidation, and functional group manipulations to install the necessary 17α-pyridine substituent. Key steps involve protection-deprotection chemistry to deliver selectivity. Acetylation of abiraterone to form the acetate salt improves absorption in the digestive tract. This process, scaled up under current Good Manufacturing Practice (cGMP) standards, keeps contamination, residual solvent, and particulate matter within tight boundaries.
Medicinal chemists spent years modifying the abiraterone molecule, aiming to improve oral bioavailability and reduce off-target effects. By introducing the 3-pyridinyl group at position 17, they created a structure that binds strongly to CYP17A1, blocking androgen and corticosteroid precursors. Chemists explored analogs, tweaking the aromatic ring or the steroid core, but came back to this configuration for its activity and manageable safety profile. In the synthesis lab, the core androstane structure can undergo selective modifications to optimize salt forms, yielding better pharmacokinetics for different market needs.
Abiraterone acetate often travels under the brand names Zytiga, Yonsa, and occasionally as CB 7598 or JNJ-212082 in research contexts. Its international nonproprietary name remains abiraterone. In catalogues and clinical guidelines, you might come across terms like 17-(3-pyridinyl)androsta-5,16-dien-3β-ol-acetate. Licensing and approved generics add prefixes and suffixes depending on local regulatory registries and manufacturing partners. Despite the different names, every product centers on the same core molecule.
Working with abiraterone in labs or production facilities means handling it as a hazardous drug. Employees need gloves, face shields, and protective clothing to limit skin or eye contact. The powder weighs out under fume hoods, following detailed standard operating procedures based on OSHA and NIOSH guidance for antineoplastic agents. Waste management follows EPA hazardous waste protocols. Every pharmacy dispensing abiraterone double-checks prescriptions and offers counseling about contraception for patients and caregivers—exposure risks go beyond swallowing the pill. Patients take regular blood tests to monitor for liver function, potassium levels, and blood pressure. Every incident of accidental exposure, spillage, or product quality concern triggers a predefined escalation and reporting process, preventing overlooked risks.
Abiraterone’s main arena lies in prostate cancer treatment, especially for men whose cancer keeps growing despite testosterone-lowering therapy. The drug changed the standard of care for advanced disease by shrinking tumors, slowing pain progression, and extending lives in pivotal phase III trials. Its use spreads further, with trials in earlier-stage prostate cancer, and, in some cases, high-risk, non-metastatic disease. Oncology teams track new uses in combination regimens alongside existing chemotherapies, PARP inhibitors, or emerging immunotherapies, always looking for a synergy that pushes out survival curves a few more months. Abiraterone’s reach doesn’t often extend beyond prostate cancer, but research groups keep an eye on CYP17A1’s role in other hormonally driven tumors, though with less success so far.
Pharmaceutical firms and academic centers keep testing abiraterone’s performance in new settings and populations. Questions about optimal duration, sequencing with other anti-androgen drugs like enzalutamide, and best practices for managing long-term side effects spark ongoing trials. Biomarker research digs deeper into why some patients respond while others don’t, looking for the best molecular signatures to guide therapy. Efforts grow around fixed-dose combinations, lower total prednisone exposure, and delivery technologies that could bypass gastrointestinal absorption. Patent cliffs and generic entry push manufacturers to compete on process optimization, improving tablet formulations for better shelf life and quicker dissolution while keeping costs manageable.
Toxicologists study abiraterone’s risks in short- and long-term exposures. The most frequent issues revolve around mineralocorticoid excess: high blood pressure, swelling from water retention, and low potassium. Rarely, patients develop liver toxicity, so routine liver function tests are a must. Animal studies highlighted risks including fetal toxicity, so pregnant women must avoid handling crushed tablets or breathing powder dust. Scientists continue looking at abiraterone’s secondary effects in real-world populations, such as older adults with multiple chronic conditions, to spot complications earlier and revise safety monitoring. Post-market surveillance led to tweaks in patient information leaflets, stressing steroid co-administration and risk management plans for cardiovascular side effects or adrenal function dips.
Looking ahead, abiraterone’s established role in metastatic prostate cancer seems secure, but change simmers at the edges. Newer anti-androgen drugs challenge its dominance, driving head-to-head trials. Biomarker-driven therapy could carve out patient groups who benefit most from abiraterone or who should go straight to next-generation options. Drug developers dig into combination strategies, where abiraterone pairs with immunotherapies, kinase inhibitors, or radioligands, searching for durable responses. Formulators trial new delivery routes, such as sublingual or transdermal systems, to improve patient adherence or reduce GI distress. As generic versions become more prevalent, access improves for patients worldwide, raising fresh hurdles for quality assurance and counterfeit detection. Still, the next decade could see abiraterone’s reach broaden or deepen—not just as a solo agent but as part of precision, tailored anti-cancer regimens that pull in genetic, metabolic, and real-world data to shape every course.
Prostate cancer keeps showing up as one of the top health concerns for men, especially those over 50. Even with so many advances, this disease refuses to back down. Every family has someone who faces a health scare like this. I know men who went from full energy to anxious worry after their diagnosis. It's tough to watch that shift and not want better tools for them. This is where abiraterone comes into the picture—offering real hope by changing how we manage advanced prostate cancer.
Abiraterone gained traction because it helps men whose prostate cancer keeps spreading, even after standard hormone therapy stops producing results. Instead of just blocking the cancer’s signals, abiraterone targets what the cancer feeds on—the production of male hormones like testosterone. These hormones push the cancer to grow. With abiraterone in the mix, testosterone production drops down a notch further than older treatments ever reached.
Patients often get this drug at a point where options feel thin. For many, standard hormone shots or surgeries don’t work forever. Cancer finds a way to work around those usual blocks, picking up speed just when men hope to feel better. Adding abiraterone to the plan means using a pill that slows down the hormone engine powering the disease.
Listen to people who have walked in those hospital hallways, and you’ll hear that the headline result with abiraterone is simple: more time. In several large studies, patients who used this medicine lived longer than those who didn’t. For the men I’ve talked with, even a few more good months mean family barbecues, grandkids’ birthdays, everyday routines. In today’s world, that's not just a number on a chart—it's dinners with loved ones and a chance to keep planning for the future.
This is not a miracle fix. Abiraterone has side effects—changes in blood pressure, lower potassium, and sometimes, stress on the liver. Doctors need to watch closely and patients often need extra medications like steroids to counteract those issues. Health insurance and cost play a big part as well. Some men find themselves stuck—wanting the latest care, but worried about the out-of-pocket totals. The question isn’t just about access but about fairness in who gets a shot at these new tools.
Some may think a new drug means the fight is over. That’s not true. Abiraterone represents years of research into how to push cancer back. Doctors use real data, published in sources like the New England Journal of Medicine and develop their approach from clinical trials and current patient experience. The FDA gave it the green light based on that kind of evidence—facts showing survival gains in men with late-stage prostate cancer.
We need more investment to keep new options coming, and efforts by charities, researchers, and government will matter just as much in the next breakthrough. Men deserve better, cheaper, easier access to effective therapies. Talking to cancer survivors, it’s clear: hope grows with each new step, but nobody should be left behind by high prices or limited supply.
Abiraterone’s story—like cancer care in general—reminds us how personal health news gets. Behind every prescription there’s always someone fighting for more than statistics: they’re fighting for time and the simple joys still within reach.
Abiraterone has changed the game for people dealing with prostate cancer. Every detail around how you take it counts, not just because it fights cancer, but because it can give you the best shot at good days. Most doctors will say—take it on an empty stomach. That means two hours after your last meal, and then wait another hour before you eat again. That gap isn’t just fussy medical advice. It’s about how much your body absorbs. A meal, especially one with fat, can make your body absorb too much. This can end up giving stronger side effects and tipping those all-important blood tests out of whack.
Watching a close family friend go through prostate cancer drove this lesson home. In the rush to beat cancer, schedules get crowded. He once took his pills with a sandwich. At his next checkup, his liver tests spiked and his blood pressure shot up. His doctor explained—just a meal with the pills throws off the balance. Missing the empty-stomach rule led to two skipped treatment days and a lot of stress. Keeping things strict with the timing gave control and less worry. He started keeping a sticky note on the fridge as a reminder. Small routines like these helped him (and those of us supporting him) feel a bit more steady in an unsteady time.
Researchers have studied this in real-world patients and in clinical trials. A high-fat meal can boost abiraterone levels by up to tenfold. That’s not a small jump. So, taking it exactly as prescribed keeps blood pressure, liver checks, and potassium levels steadier. That helps people handle the medicine, stay out of the hospital, and keep their energy up for things that matter. It always pays to double-check the label at the pharmacy. Abiraterone and prednisone—often taken together—each have time-of-day rules. The message is clear: trust the label, check in with your oncology team, and build the habit early.
Worry comes up for a reason—abiraterone can make people feel tired or cause swelling, especially if the instructions get missed. Sometimes a bloated belly, feeling short of breath, or sudden weight change shows up. These are all signs to talk with the doctor right away. Never adjust the dose yourself—you wouldn’t ignore your car’s oil light, so don’t ignore your body’s. If side effects show up, adjustments can be made safely with a phone call, not by taking pills off-script.
Smartphones make remembering easier. Set a daily alarm for the pill, plus an alert for meal timing. Keep a small calendar to jot down each dose. I’ve seen friends get creative—one used his dog’s morning walk as his “med time,” two hours after breakfast. For anyone with questions, pharmacists often have the clearest advice, especially for handling tricky meal schedules or side effects at home. Having a care partner double-check each step—especially early on—takes pressure off memory and lets people focus on life outside the hospital walls.
A well-stocked kitchen with easy breakfast options helps with planning. Set out the next day’s pills in a weekly organizer. If travel or appointments get in the way, pack a small snack and set timers to avoid unintentional slip-ups. The small things—notes, alarms, asking for help—don’t just keep numbers in range. They remind people they’re not alone in figuring all this out. Rounded routines, real conversations, and steady reminders give families some control back, right where they need it most.
For many men facing prostate cancer, the name abiraterone comes up sooner or later. This pill gives hope, but it rarely travels alone. My neighbor, Bob, had late-stage prostate cancer and started on abiraterone. Not long after, he found himself dealing with much more than just the disease. He told me he felt constantly tired, and he barely recognized his own feet, swollen with extra fluid. When his wife pointed out his mood swings and high blood pressure, he realized it wasn't all in his head. Stories like Bob’s aren’t isolated; they’re echoed in clinics around the world.
Abiraterone brings relief to prostate cancer patients, but nearly everyone notices changes in their body soon after starting. Tiredness stands out the most. At least half the men using this drug mention a deep fatigue that doesn’t go away with a good night’s sleep. Swelling in the legs, hands, or belly can show up, making shoes tight or leaving marks from socks. Doctors call this edema, but the real-life trouble is trips to buy new shoes or hours spent worrying about heart health.
High blood pressure grows more common while taking abiraterone. Each visit to the clinic, the numbers on the machine can creep up, causing concern not only for patients but for their doctors, too. Blood sugar may climb, which can push men without diabetes closer to it and those with diabetes into spikes or extra medication. Sometimes, liver numbers go up in blood tests. The drug changes how the body works, and the liver ends up working harder. When left unchecked, this can become serious, so labs are a regular part of life for patients on abiraterone.
Some men notice joint pain, almost as if aging years overnight. For others, abiraterone changes potassium levels in the blood. Lower potassium puts the heart at risk, something that lands a few men in the emergency room every year. The medicine can also cause headaches, hot flashes, or belly pain, making daily life feel unsettled.
Ignoring side effects doesn’t work. Too many men push through fatigue or swelling, chalking it up to age or cancer. But these changes hint at deeper issues. High blood pressure left untreated means higher odds for stroke. Swelling signals stress on the heart or kidneys. High blood sugar sets up a long list of risks: eye problems, nerve pain, slow healing. These side effects stretch beyond discomfort – they pile onto the worries already carried by anyone with cancer and their families. Recognizing and dealing with side effects improves not just health, but quality of life.
A strong relationship with a care team makes a difference. Blood pressure checks should happen at home and in the clinic. Lab tests need to be regular, not skipped. Doctors sometimes adjust the dose or add medicines, like potassium tablets or drugs to lower blood pressure. Eating less salt helps fight swelling, and light exercise keeps diabetes at bay.
Abiraterone works best when patients tune in to their bodies – reporting new symptoms sooner, not later. Clinicians need to listen, ask careful questions, and respond quickly. Family and friends play a big part. Bob’s wife noticed changes before anyone else. Support at home catches small problems before they become emergencies.
Abiraterone gives many a chance to keep up with life, but success rides on paying attention to these common side effects. Real stories of small shifts, like Bob’s, remind us to take each symptom seriously and keep patients living well, not just longer.
Walking into the pharmacy, most people with prostate cancer face a crowded shelf. Abiraterone, often prescribed for advanced cases, promises a better shot at staying ahead of the disease. What plenty of folks don’t realize is how delicate the balance can be between this drug and others they might already rely on. Sticking abiraterone into your daily pill routine can lead to surprises—sometimes good, sometimes risky.
The liver handles abiraterone before it gets the chance to work on prostate tumors. Medications like blood thinners, diabetes treatments, blood pressure tablets, and even cholesterol drugs usually pass through similar liver pathways. If more than one of these types ends up in your system together, your body might clear one drug faster, while letting the other linger longer. That sort of mismatch can mean side effects climb or the main cancer-fighter loses its punch.
Some antifungal medications—fluconazole or ketoconazole, for instance—turn up the levels of abiraterone in the blood. Blood pressure drugs like calcium channel blockers can do the same thing. Digoxin, a heart medication, interacts in ways that can mess with the heart’s rhythm, especially if potassium gets too low. Corticosteroids, which tag along with abiraterone prescriptions, shift levels of sodium and potassium, too. These adjustments create new risks, including swelling, weakness, or confusion.
The tight connection between abiraterone and steroids (prednisone is the usual partner) means nearly every patient ends up on at least two drugs. Add in a blood thinner for someone with atrial fibrillation, or a statin if cholesterol runs high—now it’s a juggling act. Every time a new prescription gets added, the odds for a drug interaction bump up. Skipping over those details can trigger ER visits, not just discomfort.
Physicians who follow guidelines from the American Society of Clinical Oncology suggest regular bloodwork to catch trouble before it snowballs. Potassium dips too low? Blood pressure spikes or crashes? Without that close watch, serious complications sneak up. Pharmacists also play a frontline role, catching combinations that set off alarms about liver enzymes or heart rhythm.
Folks living with prostate cancer already have a lot on their plate. Still, the responsibility to hand over a full list of medications—including supplements, herbal remedies, and OTC pills—makes a huge difference. St. John’s wort, for example, cuts abiraterone’s effect down, reducing its cancer-fighting ability. Grapefruit products, often overlooked, crank up drug levels in the blood and can quickly cause trouble.
It’s easy to grab a cold medicine from the store or take some antacids for stomach upset, but these little choices pile up. Communication with the care team sometimes feels repetitive, but sharing every detail beats risking a setback.
Cancer care asks a lot from everyone involved. Keeping a written list of medicines, asking questions during visits, and double-checking changes before filling new prescriptions make a real difference. Online patient portals help track changes, cutting down confusion between visits. Caregivers step in as advocates, helping watch for new symptoms or missed doses.
Mixing abiraterone with other medications isn’t rare; it’s the norm for most people facing advanced prostate cancer. Simple habits, strong teamwork, and honest conversation give the best shot at avoiding mix-ups and getting the benefits people count on from this important medication.
Abiraterone changed the landscape for men dealing with advanced prostate cancer. As a therapy, it works by shutting down the production of androgens, which help prostate tumors grow. While this treatment gives hope to many, it’s not a fit for everyone. Just because a medication works for some doesn’t mean it serves all. Personal health stories differ, and those details matter a lot before starting something as powerful as abiraterone.
Having seen the challenges that come with liver disease in my own family, I pay close attention to how drugs affect this organ. Abiraterone gets processed in the liver, so if your liver already struggles, the drug can build up in the body rather than get cleared out. This can cause serious side effects or even make liver function worse. Studies published in journals like The Oncologist recommend steering clear of abiraterone in people whose liver disease has advanced to a severe stage—classified as “Child-Pugh Class C.” Doctors might try adjustments or extra monitoring for milder liver impairment, but in severe cases, the risks often outweigh the benefits.
Abiraterone isn’t safe for women who are, or might become, pregnant. It targets hormones linked not only to cancer growth but also to baby development. Even being near broken or crushed tablets could be harmful. Since it disrupts testosterone production—central to male development in the womb—birth defects can happen. The FDA and similar agencies list abiraterone as strictly off-limits during pregnancy. Caregivers and family members also need to handle the medicine carefully if someone in the house could be pregnant. It’s not just about whether you take the drug, but even handling it with bare hands can cause harm.
Some folks overlook the risk of allergies to the drug itself or its fillers. A real allergic response—like difficulty breathing or face swelling—demands emergency attention. If you’ve had any bad reactions to abiraterone or ingredients in similar drugs, that’s reason enough to avoid it. I’ve seen loved ones deal with drug allergies, and it often feels unpredictable. Once that box is checked, it’s not worth testing fate again.
Heart problems and abiraterone sometimes don’t mix well. This medication often gets prescribed with steroids (like prednisone), which can mess with your body’s balance of potassium and fluid. That means people with uncontrolled high blood pressure, congestive heart failure, or irregular heart rhythms might be treading dangerous ground. Too little potassium raises the risk for serious heart rhythm problems. Doctors should run regular blood tests—something I’ve seen bring peace of mind, even if it means extra trips to the clinic. Sometimes, it’s a matter of prioritizing heart stability before starting this approach.
Health decisions get complicated fast. For those thinking about abiraterone, honest conversations with oncologists matter more than sweeping advice from the internet. Blood work, family history, medication lists—all these details shape what’s safest. Some turn to alternative therapies if abiraterone isn’t safe. Others qualify for clinical trials testing new drugs. Efforts to improve access to genetic and liver screening before starting therapy could bring real improvements. Pharmacists also play a big role— they can spot dangerous drug combinations and provide options for managing side effects. It takes a team effort and some self-advocacy, but for each person, the best solution starts with a conversation about their unique situation.
| Names | |
| Preferred IUPAC name | (3β)-17-(3-pyridyl)androsta-5,16-dien-3-ol |
| Other names |
CB7630
Zytiga Abiraterone acetate |
| Pronunciation | /əˌbaɪrəˈtɛrəˌnəʊn/ |
| Preferred IUPAC name | (3β)-17-(3-pyridyl)androsta-5,16-dien-3-ol |
| Other names |
CB7630
Zytiga Yonsa |
| Pronunciation | /əˌbaɪrəˈtɛrəˌnəʊn/ |
| Identifiers | |
| CAS Number | 154229-18-2 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Abiraterone**: ``` CC(=O)c1ccc2c(c1)C(=C(C#N)C#N)CCN2C ``` |
| Beilstein Reference | 4214114 |
| ChEBI | CHEBI:64311 |
| ChEMBL | CHEMBL254356 |
| ChemSpider | 71486757 |
| DrugBank | DB05812 |
| ECHA InfoCard | 13b1c29ef6fd-46c5-8b55-d2b9166f5692 |
| EC Number | 2.5.1.87 |
| Gmelin Reference | 743651 |
| KEGG | D09074 |
| MeSH | D000077204 |
| PubChem CID | 13257484 |
| RTECS number | WI8475000 |
| UNII | R7T0EZ6389 |
| UN number | UN3241 |
| CAS Number | 154229-18-2 |
| Beilstein Reference | 120412 |
| ChEBI | CHEBI:607457 |
| ChEMBL | CHEMBL1239970 |
| ChemSpider | 54640908 |
| DrugBank | DB05812 |
| ECHA InfoCard | ECHA InfoCard: 100004011037 |
| EC Number | 5.6.1.1 |
| Gmelin Reference | Gmelin Reference: **1918884** |
| KEGG | D09714 |
| MeSH | D000077078 |
| PubChem CID | 11250378 |
| RTECS number | AU2396750 |
| UNII | WK2XYI10QM |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C24H31NO |
| Molar mass | 437.546 g/mol |
| Appearance | White to off-white, non-hygroscopic, crystalline powder |
| Odor | Odorless |
| Density | 1.3 g/cm³ |
| Solubility in water | Practically insoluble in water |
| log P | 3.97 |
| Vapor pressure | 1.40E-11 mmHg |
| Acidity (pKa) | 13.6 |
| Basicity (pKb) | 4.03 |
| Magnetic susceptibility (χ) | -81.5e-6 cm³/mol |
| Refractive index (nD) | 1.686 |
| Viscosity | Viscous liquid |
| Dipole moment | 4.3 ± 0.5 D |
| Chemical formula | C24H31NO |
| Molar mass | 349.429 g/mol |
| Appearance | White to off-white, non-hygroscopic, crystalline powder |
| Odor | Odorless |
| Density | 1.19 g/cm3 |
| Solubility in water | Slightly soluble |
| log P | 2.6 |
| Vapor pressure | 5.01E-19 mmHg at 25°C |
| Acidity (pKa) | 13.68 |
| Basicity (pKb) | 3.71 |
| Magnetic susceptibility (χ) | -92.6×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.595 |
| Dipole moment | 4.37 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 394.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -111.2 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -8899 kJ/mol |
| Std molar entropy (S⦵298) | 274.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -167.3 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -8755 kJ·mol⁻¹ |
| Pharmacology | |
| ATC code | L02BX03 |
| ATC code | L02BX03 |
| Hazards | |
| Main hazards | May cause harm to the unborn child |
| GHS labelling | GHS05, GHS07, GHS08, Danger |
| Pictograms | Abiraterone may cause reproductive toxicity, hepatotoxicity, and requires precautionary measures for handling (gloves, avoid inhalation or skin contact). |
| Signal word | Warning |
| Hazard statements | H351: Suspected of causing cancer. |
| Precautionary statements | P201, P202, P280, P308+P313, P405, P501 |
| NFPA 704 (fire diamond) | 1-0-0-HEALTH |
| Flash point | > 293.2 °C |
| Lethal dose or concentration | LD50 (rat, oral): > 1000 mg/kg |
| LD50 (median dose) | The LD50 (median dose) of Abiraterone is ">3000 mg/kg (rat, oral)". |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 1000 mg daily |
| Main hazards | May damage fertility, Harmful to aquatic life |
| GHS labelling | GHS07 |
| Pictograms | Abiraterone|Hepatotoxicity|Reproductive toxicity|Hormonal effects|Take on empty stomach |
| Signal word | Warning |
| Hazard statements | H361: Suspected of damaging fertility or the unborn child. |
| Precautionary statements | P201, P202, P260, P264, P270, P280, P308+P313, P405, P501 |
| Flash point | > 285.6 °C |
| Lethal dose or concentration | LD50 (rat) > 2000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Abiraterone: >3000 mg/kg (rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | 10 mg/m³ |
| REL (Recommended) | 'The REL for abiraterone is 1.' |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Hydrocortisone
Prednisone Ketoconazole |
| Related compounds |
Dehydroepiandrosterone
Androstenedione Testosterone Finasteride Dutasteride Galeterone Enzalutamide Bicalutamide |
Providing high-quality chemical products and logistics solutions for global trade partners.
